The prospective randomized trial evaluating the efficacy of the mitomycin C and cisplatin regimen (MP) versus standard first-line chemotherapy in patients with advanced BRCA1/2-associated ovarian cancer (NCT04747717). (2022). Voprosy Onkologii, 68(5), 628-638. https://doi.org/10.37469/0507-3758-2022-68-5-628-638